<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>St Vincent's Hospital Melbourne cautiously prescribes thalidomide as a treatment for recalcitrant <z:e sem="disease" ids="C0037274" disease_type="Disease or Syndrome" abbrv="">dermatoses</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The guidelines used for prescribing and monitoring thalidomide for dermatological conditions at this institution are presented </plain></SENT>
<SENT sid="2" pm="."><plain>Fourteen patients were treated with thalidomide (11 women, three men) over a 5-year period </plain></SENT>
<SENT sid="3" pm="."><plain>The diagnoses of patients treated were actinic <z:e sem="disease" ids="C0033771" disease_type="Disease or Syndrome" abbrv="">prurigo</z:e>, <z:e sem="disease" ids="C0263353" disease_type="Disease or Syndrome" abbrv="">prurigo nodularis</z:e>, <z:e sem="disease" ids="C0409974" disease_type="Disease or Syndrome" abbrv="">lupus erythematosus</z:e> and <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's syndrome </plain></SENT>
<SENT sid="4" pm="."><plain>A clinical improvement was noted in 10 patients (71.4%) prescribed thalidomide </plain></SENT>
<SENT sid="5" pm="."><plain>Cessation of thalidomide treatment occurred in seven patients (50%) because of adverse effects </plain></SENT>
<SENT sid="6" pm="."><plain>Of the patients with adverse effects, four developed <z:hpo ids='HP_0000762'>abnormal nerve conduction</z:hpo> studies and three developed intolerable adverse events (such as dizziness and <z:hpo ids='HP_0002013'>vomiting</z:hpo>) </plain></SENT>
<SENT sid="7" pm="."><plain>Adverse effects from thalidomide treatment are common but, through vigilant treatment planning, patient education and regular monitoring, the risk of permanent <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> and teratogenicity from thalidomide toxicity can be minimized </plain></SENT>
</text></document>